A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: Description of the biochemical response of FGF23 to octreotide therapy and surgery

Bone

Volumn 40, Issue 1, 2007, Pages 236-241

  Elston, Marianne S ^a   Stewart, Inge J ^b   Clifton Bligh, Roderick ^b   Conaglen, John V ^a  

^a WAIKATO HOSPITAL   (New Zealand)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Fibroblast growth factor 23; Hypophosphatemia; Octreotide; Oncogenic osteomalacia; Secondary hyperparathyroidism

Indexed keywords

2,3 DICARBOXYPROPANE 1,1 DIPHOSPHONATE TECHNETIUM TC 99M; ALENDRONIC ACID; CALCITRIOL; CALCIUM; COLECALCIFEROL; FIBROBLAST GROWTH FACTOR 23; OCTREOTIDE; PARATHYROID HORMONE; PENTETREOTIDE IN 111; PHOSPHATE;

AGED; ARTICLE; CANCER SURGERY; CASE REPORT; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; MESENCHYMOMA; ONCOGENIC OSTEOMALACIA; OSTEOMALACIA; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BONE AND BONES; COMBINED MODALITY THERAPY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM; OCTREOTIDE; OSTEOMALACIA; PHOSPHATES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VITAMIN D;

EID: 33751514944     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.07.027     Document Type: Article

References (39)

1. Drezner M.R., and Feinglos M.N. Osteomalacia due to 1α,25-dihydroxycholecalciferol deficiency: association with a giant cell tumour of bone. J. Clin. Invest. 60 (1977) 1046-1053
2. Sweet R.A., Males J.L., Hamstra A.J., and DeLuca H.F. Vitamin D metabolite levels in oncogenic osteomalacia. Ann. Int. Med. 93 (1980) 279-280
3. Shane E., Parisien M., Henderson J.E., Dempster D.W., Feldman F., Hardy M.A., et al. Tumor-induced osteomalacia: clinical and basic studies. J. Bone Miner. Res. 12 (1997) 1502-1511
4. Reid I.R., Teitelbaum S.L., Dusso A., and Whyte M.P. Hypercalcemic hyperparathyroidism complicating oncogenic osteomalacia. Am. J. Med. 83 (1987) 350-354
5. Nelson A.E., Clifton Bligh R., Mirams M., Gill A., Au A., Clarkson A., et al. Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J. Clin. Endocrinol. Metab. 88 (2003) 4088-4094
6. Cheng C.L., Ma J., Wu P.C., Mason R.S., and Posen S. Osteomalacia secondary to osteosarcoma. J. Bone Joint Surg. Am. 71 (1989) 288-292
7. Huang Q.L., Feig D.S., and Blackstein M.E. Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. J. Endocrinol. Invest. 23 (2000) 263-267
8. Folpe A.L., Fanburg-Smith J.C., Billings S.D., Bisceglia M., Bertoni F., Cho J.Y., et al. Most osteomalacia-associated mesenchymal tumors are a single histopathological entity: an analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 1 (2004) 1-30
9. McGuire M.H., Merenda J.T., Etzkorn J.R., and Sundaram M. Oncogenic osteomalacia: a case report. Clin. Orthop. 244 (1989) 305-308
10. Nguyen B.D., and Wang E.A. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin. Nucl. Med. 24 (1999) 130-131
11. Rhee Y., Lee J.D., Shin K.H., Lee H.C., Huh K.B., and Lim S.K. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin. Endocrinol. 54 (2001) 551-554
12. Jan de Beur S., Streeten E.A., Civelek A.C., McCarthy E.F., Uribe L., Marx S.J., et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359 (2002) 761-763
13. Seufert J., Ebert K., Müller J., Eulert J., Hendrich C., Werner E., et al. Octreotide therapy for tumor-induced osteomalacia. N. Engl. J. Med. 345 (2001) 1883-1888
14. Paglia F., Dionisi S., and Minisola S. Octreotide for tumor-induced osteomalacia (letter). N. Engl. J. Med. 346 (2002) 1748-1749
15. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl. Acad. Sci. 98 (2001) 6500-6505
16. Jonsson K.B., Zahradik R., Larsson T., White K.E., Sugimoto T., Imanishi Y., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 348 (2003) 1656-1663
17. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87 (2002) 4957-4960
18. Ward L.M., Rauch F., White K.E., Filler G., Matzinger M.A., Letts M., et al. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna. Bone 34 (2004) 905-911
19. Weber T.J., Liu S., Indridason O.S., and Quarles L.D. Serum FGF23 in normal and disordered phosphorus homeostasis. J. Bone Miner. Res. 18 (2003) 1227-1234
20. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren Ö., Tenenhouse H.S., et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis. Endocrinology 145 (2004) 3087-3094
21. +-dependent phosphate co-transport activity and 1α,25-dihydroxyvitamin D3 production. J. Biol. Chem. 278 (2003) 2206-2211
22. Bai X.Y., Miao D., Goltzman D., and Karaplis A.C. The autosomal dominant hypophosphataemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J. Biol. Chem. 278 (2003) 9843-9849
23. Shimada T., Urakawa I., Yamazaki Y., Hasegawa H., Hino R., Yoneya T., et al. FGF-23 transgenic mice demonstrate hypophosphataemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 314 (2004) 409-414
24. Bai X., Miao D., Li J., Goltzman D., and Karaplis A.C. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145 (2004) 5269-5279
25. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113 (2004) 561-568
26. Benet-Pages A., Orlik P., Strom T., and Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphataemia. Hum. Mol. Genet. 14 (2005) 385-390
27. Larsson T., Yu X., Davis S.I., Draman M.S., Mooney S.D., Cullen M.J., et al. A novel recessive mutation in fibroblast growth factor-23 (FGF23) causes familial tumoral calcinosis. J. Clin. Endocrinol. Metab. 90 (2005) 2424-2427
28. Berndt T., Craig T.A., Bowe A.E., Vassiliadis J., Reczek D., Finnegan R., et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J. Clin. Invest. 112 (2003) 785-794
29. Rowe P.S., deZoysa P.A., Dong R., Wang H.R., White K.E., Econs M.J., et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67 (2000) 54-68
30. Quarles L.D. Evidence for a bone-kidney axis regulating phosphate homeostasis. J. Clin. Invest. 112 (2003) 642-646
31. Kumar R. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr. Opin. Nephrol. Hypertens 11 (2002) 547-553
32. Saito H., Maeda A., Ohtomo S., Hirata M., Kusano K., Kato S., et al. Circulating FGF23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J. Biol. Chem. 280 (2005) 2543-2549
33. Nishi H., Nii-Kono T., Nakanishi S., Yamazaki Y., Yamashita T., Fukumoto S., et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron. Clin. Pract. 101 (2005) c94-c99
34. Ferrari S.L., Bonjour J.P., and Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90 (2005) 1519-1524
35. Imel E.A., Peacock M., Pitukcheewanont P., Heller H.J., Ward L.M., Shulman D., et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 91 (2006) 2055-2061
36. Carpenter T.O., Ellis B.K., Insogna K.L., Philbrick W.M., Sterpka J., and Shimkets R. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J. Clin. Endocrinol. Metab. 90 (2005) 1012-1020
37. Heylen A., Dasnoy D., Hustin J., and Pochet J.-M. Tumor-related osteomalacia followed after treatment by hyperparathyroidism. Rev. Rhum. (Engl. Ed.) 66 (1999) 53-57
38. Schussheim D.H., Jacobs T.P., and Silverberg S.J. Hypocalcemia associated with alendronate (letter). Ann. Int. Med. 130 (1999) 329
39. Rosen C.J., and Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N. Engl. J. Med. 348 (2003) 1503-1504